Sector News

J&J reportedly explores sale of $2 bln sterilization division

February 20, 2018
Life sciences

Johnson & Johnson is seeking buyers for its sterilization products division, as the health-care conglomerate continues to sell off non-core assets, Bloomberg reported citing people familiar with the matter.

J&J is working with an adviser to solicit bids for the unit, which could fetch as much as $2 billion, the report said. The asset is drawing interest from strategic buyers as well as private equity firms, the people said. Bids are due this week.

No final decision has been made and J&J may choose not to divest the division, the report said.

The advanced sterilization products unit, known as ASP, makes systems and solutions to clean medical tools. Its products, which are sold globally, include the Sterrad system for sterilizing instruments and Cidex OPA solution for disinfecting scopes.

Source: RTT News

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.